Rapamycin Plus Bevacizumab in Advanced Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Advanced CancerMetastatic Cancer
Interventions
DRUG

Rapamycin (liquid)

Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)

DRUG

Bevacizumab

Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks

DRUG

Rapamycin (Tablets)

Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Chicago

OTHER

NCT00667485 - Rapamycin Plus Bevacizumab in Advanced Cancers | Biotech Hunter | Biotech Hunter